The startup offers a micro-circulating tumor cell (CTC) test that detects cancer cells released into the bloodstream, providing a quantitative assessment of cancer risk with a single blood draw. This technology enables individuals to identify the presence or absence of cancer at a cellular level, addressing the challenge of late-stage cancer detection and alleviating associated anxiety.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer screening methods often detect the disease in later stages, when treatment options are limited. Traditional screening methods can also be time-consuming, expensive, and may not cover all potential cancer sites, leading to patient anxiety and delayed diagnoses.
Solution
The company offers a micro-circulating tumor cell (CTC) test that detects cancer cells in the bloodstream, providing a quantitative assessment of cancer risk. This non-invasive test requires only a single blood draw and can identify the presence or absence of cancer at a cellular level, enabling earlier detection and potentially improving treatment outcomes. The micro-CTC test analyzes circulating tumor cells, which are cancer cells that have detached from the primary tumor and entered the bloodstream. By detecting and quantifying these cells, the test aims to provide a comprehensive assessment of cancer risk throughout the body.
Target Audience
The primary target audience includes individuals concerned about their cancer risk, those with a family history of cancer, and individuals seeking a comprehensive cancer screening solution.
Features
- Detects circulating tumor cells (CTCs) in the bloodstream.
- Provides a quantitative assessment of cancer risk.
- Requires only a single blood draw.
- Screens for cancer at a cellular level.
- Aims for early detection of cancer, before it is detectable through conventional methods.